Cox regression analysis of survival time from diagnosis and study entry in 88 risk-matched patients
. | Hazard ratio for death (95% CI) . |
|---|---|
| Overall survival from diagnosis | |
| Treatment SHDT | 0.38 (0.15-0.97)* |
| 11q deletion | 3.82 (1.51-9.67)* |
| Stage at diagnosis B | 0.88 (0.36-2.11) |
| Stage at diagnosis C | 1.69 (0.35-8.13) |
| VH mutated | 0.44 (0.15-1.28) |
| Age at diagnosis | 1.50 (0.54-4.18) |
| Overall survival from study entry | |
| Treatment SHDT | 0.38 (0.15-0.93)* |
| 11q deletion | 4.91 (1.84-13.08)* |
| Lymphocyte count at study entry higher than 50 × 109/L | 0.43 (0.17-1.10) |
| Stage at study entry B | 1.65 (0.44-6.10) |
| Stage at study entry C | 5.90 (1.42-24.44)* |
| VH mutated | 0.74 (0.23-2.41) |
| Age at study entry | 1.19 (0.48-2.93) |
| Chemotherapeutic pretreatment at study entry | 2.25 (0.91-5.52) |
. | Hazard ratio for death (95% CI) . |
|---|---|
| Overall survival from diagnosis | |
| Treatment SHDT | 0.38 (0.15-0.97)* |
| 11q deletion | 3.82 (1.51-9.67)* |
| Stage at diagnosis B | 0.88 (0.36-2.11) |
| Stage at diagnosis C | 1.69 (0.35-8.13) |
| VH mutated | 0.44 (0.15-1.28) |
| Age at diagnosis | 1.50 (0.54-4.18) |
| Overall survival from study entry | |
| Treatment SHDT | 0.38 (0.15-0.93)* |
| 11q deletion | 4.91 (1.84-13.08)* |
| Lymphocyte count at study entry higher than 50 × 109/L | 0.43 (0.17-1.10) |
| Stage at study entry B | 1.65 (0.44-6.10) |
| Stage at study entry C | 5.90 (1.42-24.44)* |
| VH mutated | 0.74 (0.23-2.41) |
| Age at study entry | 1.19 (0.48-2.93) |
| Chemotherapeutic pretreatment at study entry | 2.25 (0.91-5.52) |
For age, hazard ratios and confidence intervals (CIs) are computed for 10-year increments.
P < .05.